摘要
本文用随机双盲组间对照的方法,对53例原发性高血压进行治疗对比.地尔硫组27例(男20例,女7例;年龄50±SD7yr;病程14±7yr),用最大剂量270mg/d,4wk为一疗程。维拉帕米组26例(男25例,女1例;年龄52±6yr病程14±8yr)用最大剂量360mg/d,4wk为一疗程。总有效率前者大于后者(85％,46％)但差异不显著,降压幅度亦是前者大(2.0/2.0kPa,1.0/1.0kPa,P<0.01,0.05)2药均有升高HDL-ch的作用,副作用均较轻.
In a randomized double-blind therapeutic trial, diltiazem or verapamil was given to 53 patients with essential hypertension for 4 wk. Twenty-seven patients (M20,F 7;age 50+7 yr; duration of hypertension 14+7 yr)received maximal diltiazem 270 mg/d,and 26 patients(M 25,F 1;age 52+6 yr; duration of hypertension 14+8 yr) received maximal verapamil 360 mg/d.In diltiazem group,the response rate was 85%, while in verapamil group 46%(P>0.05).The blood pressure in the former was reduced more definitely than that in the latter(2.0/2.0 vs 1.0/1.0 kPa,P<0.01,P<0.05). The serum HDL-ch was increased without significance in both groups. No serious adverse effects were noticed with both agents.
出处
《新药与临床》
CSCD
北大核心
1990年第5期257-260,共4页
关键词
地尔硫ZHUO
高血压
维拉帕米
diltiazem/therapeutic use
verapamil / therapeutic use
hypertension/drug therapy
HDL lipoproteins
